These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Efficacy of minimally invasive pulmonary surfactant administration in preterm infants with neonatal respiratory distress syndrome: a multicenter clinical trial]. Liu HQ; Tong XM; Han TY; Zhang H; Guo M; Zhang XF; Liu XJ; Zhang X; Zhang MT; Liu F; Bao LS; Zheng J; Tian XY; Gao Q; Zhang WX; Duan Y; Sun FF; Guo W; Li L; Xiao M; Liu WL; Jiang R Zhonghua Er Ke Za Zhi; 2020 May; 58(5):374-380. PubMed ID: 32392952 [No Abstract] [Full Text] [Related]
8. Surfactant in the preterm infant: what's going on. Dani C; Barp J; Berti E; Bertini G J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():3-5. PubMed ID: 19925357 [TBL] [Abstract][Full Text] [Related]
9. Minimally Invasive Surfactant Therapy vs Sham Treatment and Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. Razak A JAMA; 2022 Apr; 327(16):1613. PubMed ID: 35471524 [No Abstract] [Full Text] [Related]
10. Minimally Invasive Surfactant Therapy vs Sham Treatment and Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. Zhou P; Han T JAMA; 2022 Apr; 327(16):1613-1614. PubMed ID: 35471523 [No Abstract] [Full Text] [Related]
11. Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis. Zhong YY; Li JC; Liu YL; Zhao XB; Male M; Song DK; Bai Y Curr Med Sci; 2019 Jun; 39(3):493-499. PubMed ID: 31209823 [TBL] [Abstract][Full Text] [Related]
12. Use of budesonide associated with a pulmonary surfactant to prevent bronchopulmonary dysplasia in premature newborns - A systematic review. Moraes LHA; Coelho RMD; Neves Dos Santos Beozzo GP; Yoshida RAM; de Albuquerque Diniz EM; de Carvalho WB J Pediatr (Rio J); 2023; 99(2):105-111. PubMed ID: 36436670 [TBL] [Abstract][Full Text] [Related]
13. Minimally Invasive Surfactant Therapy vs Sham Treatment and Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome-Reply. Dargaville PA; Carlin JB; Davis PG; JAMA; 2022 Apr; 327(16):1614-1615. PubMed ID: 35471518 [No Abstract] [Full Text] [Related]
14. Systematic review found that using thin catheters to deliver surfactant to preterm neonates was associated with reduced bronchopulmonary dysplasia and mechanical ventilation. Panza R; Laforgia N; Bellos I; Pandita A Acta Paediatr; 2020 Nov; 109(11):2219-2225. PubMed ID: 32441829 [TBL] [Abstract][Full Text] [Related]
15. Surfactant phospholipids and surface activity among preterm infants with respiratory distress syndrome who develop bronchopulmonary dysplasia. Kazzi SN; Schürch S; McLaughlin KL; Romero R; Janisse J Acta Paediatr; 2000 Oct; 89(10):1218-25. PubMed ID: 11083379 [TBL] [Abstract][Full Text] [Related]